| Ms Joy J Ferguson, RN | |
|
11727 Gay St # 482, Adelphi, OH 43101-2508 | |
| (740) 412-4137 | |
| Not Available |
| Full Name | Ms Joy J Ferguson |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 11727 Gay St # 482, Adelphi, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861698045 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 125475 (Ohio) | Secondary |
| 163W00000X | Registered Nurse | 433394 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Joy J Ferguson, RN Po Box 482, Adelphi, OH 43101-0482 Ph: (740) 412-4137 | Ms Joy J Ferguson, RN 11727 Gay St # 482, Adelphi, OH 43101-2508 Ph: (740) 412-4137 |
News Archive
In record time of two months, Pragmedic Solutions - a Dubai and US-based healthcare software solutions provider has successfully implemented the Healthcare Information System (HIS) for Emaar Healthcare Group, the healthcare subsidiary of Emaar Properties, it was announced today.
Obesity may contribute to a greater likelihood of post-operative complications for patients having pancreatic surgery, a surgeon at Thomas Jefferson University Hospital has found.
Just like snowflakes, no two people are alike, even if they're identical twins according to new genetic research from The University of Western Ontario. Molecular geneticist Shiva Singh has been working with psychiatrist Dr. Richard O'Reilly to determine the genetic sequencing of schizophrenia using identical or monozygotic twins. The study is published in this month's PLoS ONE.
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.
Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.
› Verified 4 days ago